To determine if metformin potentiates the anti-tumor activity of novel targeted agents, we tested the combination of metformin with either a bcl-2 inhibitor (Venetoclax) or CDK9 inhibitor (BAY-1143572) or PI3K inhibitor (Idelalisib). The gene discussed is BCL2; the disease is neoplasm.